Repare Therapeutics Inc. shareholders have approved the acquisition by XenoTherapeutics, Inc.
The acquisition involves all issued and outstanding common shares of Repare Therapeutics Inc.
The approval was granted at a special meeting of shareholders on January 16, 2026.
The acquisition by XenoTherapeutics, Inc. unlocks strategic synergies in the precision oncology space, positioning Repare for accelerated growth and innovation.
Shareholder Approval
The overwhelming support with 99.76% of votes indicates strong investor confidence in the acquisition's value creation potential.
Compensation Approval
Shareholders' endorsement of executive compensation alignment aligns management incentives with shareholder interests post-acquisition.
Arrangement Termination
Shareholders' backing of liquidation and dissolution provisions underlines preparedness for potential contingencies in the acquisition process.
- The approval by Repare's shareholders paves the way for finalization pending court and regulatory approvals.
- The upcoming court hearing and expected completion dates signify a swift and efficient transition post-shareholder approval.
The acquisition by XenoTherapeutics, Inc. marks a strategic milestone for Repare Therapeutics Inc., propelling its precision oncology capabilities and expanding its reach in the competitive pharmaceutical landscape.